Press release
Diabetic Nephropathy Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | Goldfinch Bio, Novartis, Serodus, CURACLE, Daiichi Sankyo, NeuroBo Pharmaceuticals, Dong-A Pharmaceutical, and others
Diabetic Nephropathy Pipeline
In the Diabetic Nephropathy Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Diabetic Nephropathy NDA approvals (if any), and product development activities comprising the technology, Diabetic Neuropathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Diabetic Nephropathy pipeline treatment landscape of the report, click here @ Diabetic Nephropathy Pipeline- https://www.delveinsight.com/report-store/diabetic-neuropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Diabetic Nephropathy Pipeline Report
• DelveInsight's Diabetic Nephropathy Pipeline analysis depicts a robust space with 25+ active players working to develop 25+ pipeline treatment therapies.
• The leading Diabetic Nephropathy Companies working in the market include Goldfinch Bio, Novartis, Serodus, CURACLE, Daiichi Sankyo, NeuroBo Pharmaceuticals, Dong-A Pharmaceutical, Sanwa Kagaku Kenkyusho Co., Ltd, Fuji Yakuhin Co Ltd, Iqvia Pty Ltd, Eli Lilly and Company, Icyte Corporation, Mitsubishi Tanabe Pharma Corporation, Novartis, Phytohealth Corporation, Cyclerion Therapeutics, Akebia Therapeutics, Dong Wha Pharmaceuticals Co Ltd, Mallinckrodt, Bayer, Reata Pharmaceuticals Inc, and others.
• Promising Diabetic Nephropathy Pipeline Therapies in the various stages of development include Propagermanium, Baricitinib, MT-3995, Canagliflozin, Nidufexor, LY3016859, PH3, IW-1973, and others.
• On January 2023, Boehringer Ingelheim announced a study of phase 2 clinical trials for BI 685509. This study is open to adults with diabetic kidney disease. The purpose of the study is to find out whether a medicine called BI 685509 improves kidney function. Three different doses of BI 685509 are tested in this study.
• On July 2023, Inversago Pharma Inc announced a study of phase 2 clinical trials for INV-202. The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due to either Type 1 diabetes mellitus or Type 2 diabetes mellitus.
• On June 2023, Shanghai Pharmaceuticals Holding Co Ltd announced a study of phase 2 clinical trials for SPH3127 matching placebo+valsartan. To preliminarily evaluate the efficacy and safety of the renin inhibitor (SPH3127 tablets) in reduction in proteinuria in patients with diabetic kidney disease with valsartan as the comparator, and determine the recommended dose.
Diabetic Nephropathy Overview
Diabetic Neuropathy, is nerve damage that can occur in people with diabetes. Different types of nerve damage cause different symptoms. Symptoms can range from pain and numbness in your feet to problems with the functions of your internal organs, such as your heart and bladder.
To explore more information on the latest breakthroughs in the Diabetic Nephropathy Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/diabetic-neuropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Diabetic Nephropathy Emerging Drugs Profile
• Nidufexor: Novartis
• SER 150: Serodus
• GFB 887: Goldfinch Bio
Diabetic Nephropathy Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies for Diabetic Neuropathy. The Diabetic Nephropathy companies which have their Diabetic Neuropathy drug candidates in the most advanced stage, i.e. Phase II include, Serodus.
Request a sample and discover the recent advances in Diabetic Nephropathy Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/diabetic-neuropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Diabetic Nephropathy Drugs and Companies
• Fulacimstat (BAY1142524): Bayer
• FG-3019: FibroGen
• MEDI3506: AstraZeneca
• SER150: Serodus ASA
• SEL: Gilead Sciences
Diabetic Nephropathy Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Diabetic Nephropathy Therapeutics Market include-
Goldfinch Bio, Novartis, Serodus, CURACLE, Daiichi Sankyo, NeuroBo Pharmaceuticals, Dong-A Pharmaceutical, Sanwa Kagaku Kenkyusho Co., Ltd, Fuji Yakuhin Co Ltd, Iqvia Pty Ltd, Eli Lilly and Company, Icyte Corporation, Mitsubishi Tanabe Pharma Corporation, Novartis, Phytohealth Corporation, Cyclerion Therapeutics, Akebia Therapeutics, Dong Wha Pharmaceuticals Co Ltd, Mallinckrodt, Bayer, Reata Pharmaceuticals Inc, and others.
Dive deep into rich insights for drugs for Diabetic Nephropathy Pipeline, click here for Diabetic Nephropathy Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/diabetic-neuropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Diabetic Nephropathy Pipeline Report
• Coverage- Global
• Diabetic Nephropathy Companies- Goldfinch Bio, Novartis, Serodus, CURACLE, Daiichi Sankyo, NeuroBo Pharmaceuticals, Dong-A Pharmaceutical, Sanwa Kagaku Kenkyusho Co., Ltd, Fuji Yakuhin Co Ltd, Iqvia Pty Ltd, Eli Lilly and Company, Icyte Corporation, Mitsubishi Tanabe Pharma Corporation, Novartis, Phytohealth Corporation, Cyclerion Therapeutics, Akebia Therapeutics, Dong Wha Pharmaceuticals Co Ltd, Mallinckrodt, Bayer, Reata Pharmaceuticals Inc, and others.
• Diabetic Nephropathy Pipeline Therapies- Propagermanium, Baricitinib, MT-3995, Canagliflozin, Nidufexor, LY3016859, PH3, IW-1973, and others.
• Diabetic Nephropathy Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Diabetic Nephropathy Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/diabetic-neuropathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Diabetic Neuropathy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Diabetic Neuropathy- DelveInsight's Analytical Perspective
7. Late Stage Products (Pre Registration)
8. Drug name : Company name
9. Drug profiles in the detailed report…..
10. End Stage Products (Phase III)
11. Drug name : Company name
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. GFB 887: Goldfinch Bio
15. Drug profiles in the detailed report…..
16. Early Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Diabetic Neuropathy Key Companies
21. Diabetic Neuropathy Key Products
22. Diabetic Neuropathy- Unmet Needs
23. Diabetic Neuropathy- Market Drivers and Barriers
24. Diabetic Neuropathy- Future Perspectives and Conclusion
25. Diabetic Neuropathy Analyst Views
26. Diabetic Neuropathy Key Companies
27. Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetic Nephropathy Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | Goldfinch Bio, Novartis, Serodus, CURACLE, Daiichi Sankyo, NeuroBo Pharmaceuticals, Dong-A Pharmaceutical, and others here
News-ID: 3137300 • Views: …
More Releases from DelveInsight Business Research
Insulin Resistance Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Tri …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Insulin Resistance pipeline constitutes 8+ key companies continuously working towards developing 10+ Insulin Resistance treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Insulin Resistance Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Insulin Resistance Market.
The Insulin…
Hepatocellular Carcinoma Market Growth to Surge During Forecast Period (2024-203 …
DelveInsight's "Hepatocellular Carcinoma Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Hepatocellular Carcinoma, historical and forecasted epidemiology as well as the Hepatocellular Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Hepatocellular Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hepatocellular Carcinoma Market Forecast
https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
High-Grade Glioma Pipeline 2025: Therapies Under Investigation, Clinical Trials …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, High-Grade Glioma pipeline constitutes 150+ key companies continuously working towards developing 150+ High-Grade Glioma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The High-Grade Glioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers…
Global Injectable Drug Delivery Devices Market to grow at a CAGR of 6.12% by 203 …
According to DelveInsight's analysis, The intraocular lens market is witnessing significant growth due to the rising prevalence of eye disorders such as cataracts, presbyopia, and astigmatism, which are driving demand for corrective surgeries. This trend is supported by greater awareness and improved access to eye care services, particularly in developing regions, allowing more patients to pursue treatment. Advances in lens materials and designs-including multifocal, toric, and extended depth-of-focus lenses-are improving…
More Releases for Diabetic
Diabetic Socks Market Dynamics Shaped by Rising Diabetic Population - Persistenc …
The diabetic socks market is gaining significant traction worldwide, driven by the rising prevalence of diabetes and related complications such as diabetic neuropathy and foot ulcers. Designed specifically to cater to the needs of diabetic patients, these socks play a crucial role in foot protection by preventing blistering, reducing moisture accumulation, and providing cushioning to minimize the risk of ulcers. This article delves deeply into the diabetic socks market, exploring…
Leading Element Driving Change in the Diabetic Footwear Market in 2025: Rising D …
Which drivers are expected to have the greatest impact on the over the diabetic footwear market's growth?
The surge in people with diabetes will spur the expansion of the diabetic footwear market in the future. Diabetes, characterised by high blood sugar levels, is a long-term health issue. Diabetic footwear can prevent severe foot-related issues caused by diabetes and offer several advantages such as enhanced blood flow, ample space for the toes,…
Diabetic Food Market
Future Market Insights (FMI) delivers key insights on the global diabetic food market in its latest report titled “Diabetic Food Market: Global Industry Analysis and Opportunity Assessment, 2014 – 2020”. The global diabetic food market is expected to amplify at a CAGR of 5.9% during the forecast period in terms of value due to various factors, regarding which FMI offers fundamental insights in detail in this report.
On the basis of…
Diabetic Food Market
Diabetes refers to a metabolic disease which leads to high blood sugar levels. The main cause behind diabetes is the insufficient insulin or no response in the body cells where the insulin is produced. Diabetic foods are dietary products rich in carbohydrates and sugar content. They help in controlling rising blood glucose. Diabetic food is low in calorie sweeteners and diet beverages. These products are consumed by diabetic patients and…
Demand for Diabetic Socks Due to Rising Prevalence of Diabetic Neuropathy Expect …
According to the latest market report published by Persistence Market Research titled ‘Diabetic Socks Market: Global Industry Analysis 2012-2016 and Forecast 2017-2025,’ the global diabetic socks market is expected to expand at a CAGR of approximately 4.8% during the forecast period 2017-2025.
To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/19282
Global Diabetic Socks Market: Factors Impacting the Market
The primary factors driving the growth of the global diabetic socks market are increasing…
Diabetic Food Market -
In recent times, diabetes has emerged as one of the most challenging health conditions across the world. According to the WHO, a total of 415 million cases of diabetes were reported globally in 2015. The count is rising at an alarming rate and is expected to reach 642 million in the next 25 years. Till now no medication has been found that can completely cure diabetes. It can only be…
